The University of Southampton
University of Southampton Institutional Repository
Warning ePrints Soton is experiencing an issue with some file downloads not being available. We are working hard to fix this. Please bear with us.

The early use of Antibiotics for at Risk CHildren with InfluEnza-like illness (ARCHIE): a double-blind randomised placebo-controlled trial

The early use of Antibiotics for at Risk CHildren with InfluEnza-like illness (ARCHIE): a double-blind randomised placebo-controlled trial
The early use of Antibiotics for at Risk CHildren with InfluEnza-like illness (ARCHIE): a double-blind randomised placebo-controlled trial
Introduction: the UK government stockpiles co-amoxiclav to treat bacterial complications during influenza pandemics. This pragmatic trial examines whether early co-amoxiclav use reduces re-consultation due to clinical deterioration in ‘at risk’ children presenting with influenza-like illness (ILI) in primary or ambulatory care.

Methods: ‘At risk’ children aged 6 months to 12 years presenting within five days of ILI onset were randomly assigned to oral co-amoxiclav 400/57 or placebo twice daily for five days (dosing based on age +/- weight). ‘At risk’ groups included children with respiratory, cardiac, and neurological conditions. Randomisation was stratified by region and used a non-deterministic minimisation algorithm to balance age and current seasonal influenza vaccination status. Our target sample size was 650 children, which would have allowed us to detect a reduction in the proportion of children re-consulting due to clinical deterioration from 40% to 26% with 90% power and 5% two-tailed alpha error, including allowance for 25% loss to follow-up and an inflation factor of 1.041. Participants, caregivers and investigators were blinded to treatment allocation. Intention-to-treat analysis included all randomised participants with primary outcome data on re-consultation due to clinical deterioration within 28 days. Safety analysis included all randomised participants. Trial registration: ISRCTN 70714783. EudraCT 2013-002822-21.

Results: we recruited 271 children between 11 February 2015 and 20 April 2018. Primary outcome data were available for 265 children. Only 61/265 children (23.0%) re-consulted due to clinical deterioration. No evidence of a treatment effect was observed for re-consultation due to clinical deterioration (co-amoxiclav 33/133 (24.8%), placebo 28/132 (21.2%), adjusted risk ratio [RR] 1.16, 95% confidence interval [CI] 0.75 to 1.80). There was also no evidence of a difference between groups in the proportion of children for whom one or more adverse events were reported (co-amoxiclav 32/136 (23.5%), placebo 22/135 (16.3%), adjusted RR 1.45, 95% CI 0.90 to 2.34). Sixty-six adverse events were reported in total (co-amoxiclav n=37, placebo n=29). Nine serious adverse events were reported per group; none were considered related to study medication.

Conclusion: our trial did not find evidence that treatment with co-amoxiclav reduces risk of re-consultation due to clinical deterioration in ‘at risk’ children who present early with ILI during influenza season. Our findings therefore do not support early co-amoxiclav use in children with seasonal ILI.
0903-1936
Little, Paul
1bf2d1f7-200c-47a5-ab16-fe5a8756a777
Moore, Michael
1be81dad-7120-45f0-bbed-f3b0cc0cfe99
Wang, Kay
d5db72ee-6755-4f79-b8ce-d04e47167927
Hay, Alistair D.
4ac520e7-944a-4732-b074-5436b4570f76
Butler, Christopher C.
c8cc70b1-5fb9-4b03-bb80-11c6aabb7e6f
Little, Paul
1bf2d1f7-200c-47a5-ab16-fe5a8756a777
Moore, Michael
1be81dad-7120-45f0-bbed-f3b0cc0cfe99
Wang, Kay
d5db72ee-6755-4f79-b8ce-d04e47167927
Hay, Alistair D.
4ac520e7-944a-4732-b074-5436b4570f76
Butler, Christopher C.
c8cc70b1-5fb9-4b03-bb80-11c6aabb7e6f

Little, Paul, Moore, Michael, Wang, Kay, Hay, Alistair D. and Butler, Christopher C. (2021) The early use of Antibiotics for at Risk CHildren with InfluEnza-like illness (ARCHIE): a double-blind randomised placebo-controlled trial. European Respiratory Journal, 58 (4), [2002819].

Record type: Article

Abstract

Introduction: the UK government stockpiles co-amoxiclav to treat bacterial complications during influenza pandemics. This pragmatic trial examines whether early co-amoxiclav use reduces re-consultation due to clinical deterioration in ‘at risk’ children presenting with influenza-like illness (ILI) in primary or ambulatory care.

Methods: ‘At risk’ children aged 6 months to 12 years presenting within five days of ILI onset were randomly assigned to oral co-amoxiclav 400/57 or placebo twice daily for five days (dosing based on age +/- weight). ‘At risk’ groups included children with respiratory, cardiac, and neurological conditions. Randomisation was stratified by region and used a non-deterministic minimisation algorithm to balance age and current seasonal influenza vaccination status. Our target sample size was 650 children, which would have allowed us to detect a reduction in the proportion of children re-consulting due to clinical deterioration from 40% to 26% with 90% power and 5% two-tailed alpha error, including allowance for 25% loss to follow-up and an inflation factor of 1.041. Participants, caregivers and investigators were blinded to treatment allocation. Intention-to-treat analysis included all randomised participants with primary outcome data on re-consultation due to clinical deterioration within 28 days. Safety analysis included all randomised participants. Trial registration: ISRCTN 70714783. EudraCT 2013-002822-21.

Results: we recruited 271 children between 11 February 2015 and 20 April 2018. Primary outcome data were available for 265 children. Only 61/265 children (23.0%) re-consulted due to clinical deterioration. No evidence of a treatment effect was observed for re-consultation due to clinical deterioration (co-amoxiclav 33/133 (24.8%), placebo 28/132 (21.2%), adjusted risk ratio [RR] 1.16, 95% confidence interval [CI] 0.75 to 1.80). There was also no evidence of a difference between groups in the proportion of children for whom one or more adverse events were reported (co-amoxiclav 32/136 (23.5%), placebo 22/135 (16.3%), adjusted RR 1.45, 95% CI 0.90 to 2.34). Sixty-six adverse events were reported in total (co-amoxiclav n=37, placebo n=29). Nine serious adverse events were reported per group; none were considered related to study medication.

Conclusion: our trial did not find evidence that treatment with co-amoxiclav reduces risk of re-consultation due to clinical deterioration in ‘at risk’ children who present early with ILI during influenza season. Our findings therefore do not support early co-amoxiclav use in children with seasonal ILI.

Text
ARCHIE MS v0.13 clean copy for ERJ - Accepted Manuscript
Restricted to Repository staff only until 18 February 2022.
Request a copy

More information

Accepted/In Press date: 18 February 2021
e-pub ahead of print date: 18 March 2021

Identifiers

Local EPrints ID: 447566
URI: http://eprints.soton.ac.uk/id/eprint/447566
ISSN: 0903-1936
PURE UUID: 0c362408-2b3b-4c3b-ab54-e22d68478187
ORCID for Michael Moore: ORCID iD orcid.org/0000-0002-5127-4509

Catalogue record

Date deposited: 16 Mar 2021 17:32
Last modified: 10 Jan 2022 02:49

Export record

Contributors

Author: Paul Little
Author: Michael Moore ORCID iD
Author: Kay Wang
Author: Alistair D. Hay
Author: Christopher C. Butler

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×